Nikita Shah - 12 Aug 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Reporting relationship: Executive Vice President
Issuer ticker: AMRX
Reported as of: 12 Aug 2026
Net transaction value: -$2,563,517
SEC form: 4
Accepted by SEC: 13 Aug 2026, 16:22:00 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Denis Butkovic, Attorney-in-Fact

Key filing fact

Nikita Shah filed Form 4 for Amneal Pharmaceuticals, Inc. (AMRX) on 13 Aug 2026.

Key facts

This page summarizes Nikita Shah's Form 4 filing for Amneal Pharmaceuticals, Inc. (AMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 16:22.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: -$2,563,517.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001738061 Primary reporting owner

Shah Nikita

Relationship: Executive Vice President
Address: C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BLVD., BRIDGEWATER
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRX transaction

Class A Common Stock

Sale

Transaction value: $2,563,517
Shares: -146,403
Change %: -37%
Price: $17.51
Shares after: 253,390
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.